Efficacy of 10-day Sequential Treatment for Helicobacter pylori Eradication

Lubna Naz; Ayesha Waqar; Maryam Mahboob; Asif Raza Bhatti; Fazeelat Iftikhar; Zahra Rafique

doi:10.51253/pafmj.v74i5.10061

Authors

Lubna Naz Department of Medicine, Islamabad Medical Complex (NESCOM), Islamabad Pakistan
Ayesha Waqar Department of Medicine, Islamabad Medical Complex (NESCOM), Islamabad Pakistan
Maryam Mahboob Department of Medicine, Islamabad Medical Complex (NESCOM), Islamabad Pakistan
Asif Raza Bhatti Department of Medicine, Islamabad Medical Complex (NESCOM), Islamabad Pakistan
Fazeelat Iftikhar Department of Medicine, Islamabad Medical Complex (NESCOM), Islamabad Pakistan
Zahra Rafique Department of Medicine, Islamabad Medical Complex (NESCOM), Islamabad Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i5.10061

Keywords:

Anti-bacterial agents, Gastritis Helicobacter pylori, Sequential therapy, Triple therapy.

Abstract

Objective: To assess the effectiveness and tolerability of a ten-day sequential regimen for the eradication of Helicobacter pylori.

Study Design: Quasi-experimental study.

Place and Duration of Study: Department of Medicine, NESCOM Hospital, Islamabad Medical Complex, Pakistan from Aug 2021 to Aug 2022.

Methodology: The patients were divided into two groups. The sequential therapy group (Group-A) was administered dual therapy including a proton pump inhibitor (Lansoprazole 30mg) plus Amoxicillin 1 gram given twice daily for first five days, followed by a triple therapy including Lansoprazole 30mg, Levofloxacin 500 mg and Tinidazole 500mg, all twice daily for remaining five days. Whereas traditional therapy group (Group-B) was given Lansoprazole 30 mg, Clarithromycin 500 mg, and Amoxicillin 1000 mg twice daily for total 14 days.

Results: A total of 200 Helicobacter pylori positive cases were included. The mean age of all patients was 36.60±12.49 years whereas mean Body Mass Index was 28.19±4.02. A total of 140 patients had successful treatment in both groups out of which 87(87%) were in sequential treatment group and 53(53%) in the traditional treatment group (p-value <0.001). In terms of side effects, there were 18(8%) patients who suffered minor side effects out of which metallic taste was most common, 14(7%), followed by bloating and diarrhea. Both groups had comparable side effects (p =1.00).

Conclusion: Even with comparable side effects, the innovative 10-day sequential medication for the treatment of H. pylori is more successful than traditional triple regimen.

Downloads

Download data is not yet available.

References

Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol 2013; 69: 1709-1715.

https://doi.org/10.1007/s00228-013-1524-6

Daniyal M, Ahmad S, Ahmad M, Asif HM, Akram M, Rehman SU, et al. Risk factors and epidemiology of gastric cancer in Pakistan. Asian Pac J Cancer Prev 2015; 16(12): 4821-4824.

https://doi.org/10.7314/APJCP.2015.16.12.4821

Farhoud NS, Ibrahim OM, Ezzat SE. Efficacy and cost-effectiveness comparison of 10-day, 14-day sequential versus 14-day triple therapies for treating Helicobacter pylori infection in Egyptian patients. J Clin Gastroenterol 2020; 54(9): 806-812.

https://doi.org/10.1097/MCG.0000000000001278

Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021; 70(1): 40-54.

https://doi.org/10.1136/gutjnl-2020-321372

Chey WD, Leontiadis GI, Howden CW. ACG Clinical Guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112: 212–238. https://doi.org/10.1038/ajg.2016.563

Butt AM, Sarwar S, Nadeem MA: Concomitant therapy versus triple therapy: efficacy in H. Pylori eradication and predictors of treatment failure. J Coll Physicians Surg Pak 2021; 31: 128-131.

https://doi.org/10.29271/jcpsp.2021.02.128

Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: a prospective randomized study. Turk J Gastroenterol 2018; 29: 549-554.

https://doi.org/10.5152/2Ftjg.2018.17707

Latif S, Akther N, Amjed S. Efficacy of standard triple therapy versus Levofloxacin based alternate therapy against Helicobacter pylori infection. J Pak Med Assoc 2018; 68: 1295-1299.

Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. Pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019; 19: 447.

https://doi.org/10.1186/s12879-019-4085-1

Kim JS, Kim BW, Ham JH. Sequential therapy for Helicobacter pylori infection in Korea: systematic review and meta-analysis. Gut Liver 2013; 7(5): 546-551.

https://doi.org/10.5009/2Fgnl.2013.7.5.546

McNicholl AG, Marin AC, Molina-Infante J. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63(2): 244-249. https://doi.org/10.1136/gutjnl-2013-304820

Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, et al. Mass eradication of Helicobacter pylori to prevent gastric cancer: theo-retical and practical considerations. Gut Liver 2016; 10(1): 12-26.

https://doi.org/10.5009/2Fgnl15091

Seddik H, Ahid S, El Adioui T. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol 2013; 69: 1709–1715. https://doi.org/10.1007/s00228-013-1524-6

Greenberg ER, Anderson GL, Morgan DR. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507–514.

Liou J-M, Chen C-C, Chang C-Y. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2016; 65(11): 1784–1792.

https://doi.org/10.1136/gutjnl-2015-310142

Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study. Turk J Gastroenterol 2018; 29(5): 549–554.

https://doi.org/10.5152/2Ftjg.2018.17707

Salem EM, Yar T, Bamosa AO, Al-Quorain A, Yasawy MI, Alsulaiman RM, et al. Comparative study of Nigella Sativa and tri -ple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia. Saudi J Gastroenterol 2010; 16(3): 207-214. https://doi.org/10.4103/1319-3767.65201

Eisig JN, Navarro-Rodriguez T, Teixeira ACS. Standard triple therapy versus sequential therapy in Helicobacter pylori eradication: a double-blind, randomized, and controlled trial. Gastroenterol Res Pract 2015; 2015(1): 818043.

https://doi.org/10.1155/2015/818043

Choi HS, Chun HJ, Park SH. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18(19): 2377–2382.

https://doi.org/10.3748/2Fwjg.v18.i19.2377

Liou J-M, Chen C-C, Chen M-J. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205–213.